Headline findings from the CBT-I literature
70–80%
Clinical response to CBT-I
Published reviews (Morin et al.)
1st-line
American Academy of Sleep Medicine (AASM) guideline
Edinger et al., AASM 2021
24 mo
CBT-I outperforms pharma at long follow-up
Morin et al., JAMA 1999
The studies below are the ones we cite when we say CBT-I is the most effective non-pharmacological treatment for chronic insomnia. The section after that shows how each finding turns into a specific behavior inside the program.
The four landmark studies
The papers SleepShift is built on.
01Meta-analysis · 20 RCTs · n=1,162
Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis
Trauer JM, Qian MY, Doyle JS, Rajaratnam SMW, Cunnington D. Annals of Internal Medicine, 2015;163(3):191–204
What it found: Across 20 randomized trials, CBT-I produced large, durable improvements in every primary insomnia metric — sleep onset latency, wake after sleep onset, total sleep time, and sleep efficiency. Effect sizes were sustained at follow-up months after treatment ended.
Why it matters here: Trauer remains the most cited efficacy reference for multicomponent CBT-I. It's why every major sleep society now treats CBT-I as first-line.
02AASM Clinical Practice Guideline
Behavioral and Psychological Treatments for Chronic Insomnia Disorder in Adults
Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U, Heald JL, Martin JL. Journal of Clinical Sleep Medicine, 2021;17(2):255–262
What it found: The American Academy of Sleep Medicine issued a STRONG recommendation for multicomponent CBT-I as first-line treatment for chronic insomnia disorder in adults, ahead of pharmacotherapy.
Why it matters here: This is the guideline US clinicians follow. SleepShift implements the exact multicomponent protocol AASM defines: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relaxation. The AASM's April 2026 combination-treatment guideline points the same way — CBT-I alone is preferred, and it suggests against routinely adding medication to it.
03Randomized controlled trial · 24-month follow-up
Behavioral and Pharmacological Therapies for Late-Life Insomnia: A Randomized Controlled Trial
Morin CM, Colecchi C, Stone J, Sood R, Brink D. JAMA, 1999;281(11):991–999
What it found: Adults with chronic insomnia were randomized to CBT, temazepam, both, or placebo. At end of treatment, all active arms outperformed placebo. By 24-month follow-up, CBT alone produced the most sustained sleep improvements — while the medication arms had largely returned to baseline.
Why it matters here: The classic durability finding. CBT-I doesn't just match medication short-term — its benefits were still holding at 24 months after treatment, while the medication arms had faded.
04Meta-analysis · Sleep restriction therapy alone
The Clinical Effects of Sleep Restriction Therapy for Insomnia: A Meta-Analysis of Randomised Controlled Trials
Maurer LF, Espie CA, Omlin X, Emsley R, Kyle SD. Sleep Medicine Reviews, 2022;62:101597
What it found: Sleep restriction therapy administered as a standalone treatment — without the rest of the CBT-I bundle — produced clinically meaningful improvements in sleep efficiency, sleep onset latency, and ISI score. SRT is identified as the most potent single component of CBT-I.
Why it matters here: Validates the heaviest lever inside the SleepShift protocol. The sleep window calibration that runs from Phase 2 forward is the same SRT mechanism this meta-analysis confirms.
See your insomnia profile in 3 minutes.
The assessment maps your pattern to the components above and shows you what the 8-week protocol would look like for your case. Free.
$0 first week · then $29.99/month · cancel anytime · 14-day money-back guarantee